SequelSEC

TREACE MEDICAL CONCEPTS, INC. TMCI

Surgical & Medical Instruments & Apparatus · CIK 0001630627 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$205.31M
Fiscal year ended 2026-06-30
Operating income
-$53.72M
Fiscal year ended 2026-06-30
Free cash flow
-$25.05M
Fiscal year ended 2026-06-30

TREACE MEDICAL CONCEPTS, INC. (TMCI) reported revenue of $205.31M and net income of -$59.52M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TREACE MEDICAL CONCEPTS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

TREACE MEDICAL CONCEPTS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$205.31M
Cost of revenue$42.19M
Gross profit$163.12M
Operating income-$53.72M
Net income-$59.52M
Research & development$18.22M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$198.62M
General & administrative$62.24M
Selling & marketing$136.39M

Balance

TREACE MEDICAL CONCEPTS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$12.61M
Total assets$181.06M
Current assets$120.45M
Total liabilities$113.32M
Current liabilities$41.50M
Total equity incl. NCI$67.74M
Temporary (mezzanine) equityUnavailable
Inventory$39.54M
Accounts receivable$28.73M
Goodwill$12.82M
Long-term debt$56.04M
Accounts payable$16.06M

Cash flow

TREACE MEDICAL CONCEPTS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$14.58M
Capital expenditures$10.47M
Investing cash flow$17.65M
Financing cash flow$1.48M
Net change in cash$4.56M
Stock-based compensation$30.05M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$8.37M

Derived

TREACE MEDICAL CONCEPTS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$25.05M
Gross margin79.5%
Operating margin-26.2%
FCF margin-12.2%
SBC / revenue14.6%
Current ratio2.90x
Revenue YoY growth-4.0%
Net margin-29.0%
R&D / revenue8.9%
CapEx / revenue5.1%
Long-term debt / equity0.83x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TMCI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-27View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.